Table 4.
Use of Meropenem/Vaborbactam and Cefiderocol as empirical and targeted therapies.
| Preferred Empirical Use of Cefiderocol | Isolates | N (%) |
| Total (23/23) | Kp VIM or NDM + | 3 (13.04) |
| P. aeruginosa MDR | 5 (21.74) | |
| A. baumannii MDR | 20 (86.96) | |
| S. maltophilia | 1 (4.35) | |
| Other Enterobacterales | 1 (4.35) | |
| Preferred empirical use of M/V | Isolates | N (%) |
| Total (23/23) | Kp KPC+ | 19 (82.61) |
| P. aeruginosa MDR | 4 (17.39) | |
| Other Enterobacterales | 4 (17.39) | |
| Preferred targeted use of Cefiderocol | Isolates | N (%) |
| Total (23/23) | Kp VIM or NDM + | 3 (13.04) |
| P. aeruginosa MDR | 2 (8.7) | |
| A. baumannii MDR | 20 (86.96) | |
| S. maltophilia | 1 (4.35) | |
| Other Enterobacterales | 0 (0) | |
| Preferred targeted use of M/V | Isolates | N (%) |
| Total (23/23) | Kp KPC+ | 19 (82.61) |
| P. aeruginosa MDR | 4 (17.39) | |
| Other Enterobacterales | 3 (13.04) | |
| Cefiderocol combination therapy against CRAB | Molecules | N (%) |
| Total (23/23) | Rifampicin | 3 (13.04) |
| Fosfomycin | 16 (69.57) | |
| Polymixin | 12 (52.17) | |
| Ampicillin/sulbactam | 9 (39.13) | |
| Tigecyclin | 6 (26.09) | |
| Never in combination | 1 (4.35) | |
| Cefiderocol combination therapy against Pseudmonas MDR | Molecules | N (%) |
| Total (23/23) | Aminoglycosides | 8 (34.78) |
| Fosfomycin | 16 (69.57) | |
| Polymixin | 8 (34.78) | |
| Never in combination | 2 (8.70) | |
| Cefiderocol combination therapy against NDM/VIM + | Molecules | N (%) |
| Total (23/23) | Aztreonam | 7 (30.43) |
| Fosfomycin | 10 (43.48) | |
| Polymixin | 7 (30.43) | |
| Aminoglycosides | 5 (21.74) | |
| Tigecyclin | 3 (13.04) | |
| Never in combination | 4 (17.39) | |
| Cefiderocol combination therapy against KPC and OXA-48 + | Molecules | N (%) |
| Total (23/23) | Fosfomycin | 15 (65.22) |
| Polymixin | 9 (39.13) | |
| Aminoglycosides | 7 (30.43) | |
| Tigecyclin | 3 (13.04) | |
| Never in combination | 4 (17.39) | |
| M/V combination therapy against KPC + | Molecules | N (%) |
| Total (23/23) | Fosfomycin | 13 (56.52) |
| Polymixin | 6 (26.09) | |
| Aminoglycosides | 9 (39.13) | |
| Tigecyclin | 4 (17.39) | |
| Never in combination | 6 (26.09) |
Abbreviations: M/V: meropenem/vaborbactam; KPC: K. pneumoniae Carbapenemases; NDM: New-Dehli Metallo-Beta-Lactamases; VIM: Verona Integron-Encoded Beta-Lactamases; MDR: multi-drug resistant; CRAB: Carbapenem-Resistant A. baumannii.